Heart shock drug shows promise in reducing death and readmission
NCT ID NCT07450417
First seen Mar 11, 2026 · Last updated May 23, 2026 · Updated 11 times
Summary
This study looks at whether starting the drug empagliflozin early in patients with cardiogenic shock (a severe heart pump failure) can lower the risk of death or repeat hospital stays for heart failure within 3 months. Researchers reviewed records of 418 adults treated in intensive care units. The goal is to see if adding this medication to standard care improves outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOGENIC SHOCK are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chru Nancy
Vandœuvre-lès-Nancy, 54500, France
Conditions
Explore the condition pages connected to this study.